Synageva BioPharma Corp. (GEVA)
-NasdaqGS 39.87 
0.04(0.10%) May 17, 4:00PM EDT|After Hours
:
39.87 0.00 (0.00%) May 17, 4:32PM EDT
| Prev Close: | 39.83 |
|---|
| Open: | 40.33 |
|---|
| Bid: | 10.17 x 2000 |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | 59.43 |
|---|
| Beta: | 0.73 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 39.79 - 40.37 |
|---|
| 52wk Range: | 34.01 - 58.00 |
|---|
| Volume: | 108,993 |
|---|
| Avg Vol (3m): | 100,627 |
|---|
| Market Cap: | 1.09B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -2.08 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 3 Horrendous Health-Care Stocks This Weekat Motley Fool(Sat 8:45AM EDT)
- Synageva BioPharma™ Joins the International MPS Network in Support of MPS Awareness Day 2013Business Wire(Wed, May 15)
- SYNAGEVA BIOPHARMA CORP FinancialsEDGAR Online Financials(Tue, May 14)
- Synageva BioPharma Corp Enters Oversold Territory (GEVA)at TheStreet(Fri, May 10)
- Synageva downgraded to Neutral from Overweight at JPMorganat theflyonthewall.com(Fri, May 10)
- Synageva BioPharma™ Announces One Year of Treatment Data with Sebelipase Alfa in Late Onset LAL DeficiencyBusiness Wire(Thu, May 9)
- Synageva BioPharma™ Reports First Quarter 2013 Financial ResultsBusiness Wire(Tue, May 7)
- SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and EEDGAR Online(Tue, May 7)
- Snag GEVA Even Cheaper Than Its Secondary?at Forbes(Wed, May 1)
- GEVA Crosses Below Key Moving Average Levelat TheStreet(Wed, May 1)
- Making the Call to Come Back to Biotech: An Expert Analyst Discusses His Positive Outlook on the Biotech Sector with The Wall Street TranscriptWall Street Transcript(Tue, Apr 30)
- SAC Capital Advisors likes this pharma stockat MarketWatch(Thu, Apr 18)
- Mega-Hedge Fund Focusing on the Life Sciencesat Motley Fool(Thu, Apr 18)
- SYNAGEVA BIOPHARMA CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other EventsEDGAR Online(Mon, Apr 8)
- Late Onset LAL Deficiency (CESD) Literature Review Published in the Journal of HepatologyBusiness Wire(Tue, Mar 26)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 61.45 |
|---|
| Ex-Dividend Date: | 30-Dec-08 |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -3.25 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.78 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Synageva BioPharma Corp., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical needs.
View More